Trastuzumab deruxtecan
Enhertu · Antibody-drug conjugate (HER2/DXd)
Emerging AKI/proteinuria reports — under-published.
Zometa · Zol
Bisphosphonate · approved 2001 · 11 citations · FAERS AKI reporting ROR 2.13 (95% CI 2.02–2.25, 1,314 AKI reports)
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
The tubule-toxic bisphosphonate — ATN driven by dose and infusion speed.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Nephrotoxicity is the dose-limiting toxicity but largely avoidable. Reported rate: renal toxicity in 17% of 852 patients with newly diagnosed multiple myeloma given zoledronic acid 4 mg every 4 weeks, versus 10% on denosumab (Raje 2018, PMID 29429912).Source: Raje et al., Lancet Oncol 2018
AKI days to weeks after an infusion.
Distilled from: “Acute — days to weeks after infusion(s).”
Zoledronate ATN is often partially reversible when doses are held early — creatinine tends to recover partially after withdrawal — but the recovery is incomplete and dose-dependent.PMID 12787420 (opens PubMed in a new tab)
4 mg per dose, infused over no less than 15 minutes
Exceeding the 4 mg dose (e.g. the 8 mg arm) or shortening the infusion below 15 minutes sharply raises renal events — the basis for the fixed 4 mg over >=15 minutes standard.PMID 18685574 (opens PubMed in a new tab)
Distilled from the agent's cited literature — educational, not a substitute for the primary sources.
Recovery across agentsThis agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Notable serum-creatinine rise in 6 of 67 patients (9%) on IV zoledronic acid for bone metastases at one center, four of them in patients treated for more than 2 years.
Not the same figure as §01's 17%. §01 is any reported renal toxicity in the 852 zoledronic-acid patients of a myeloma trial; this row is a notable creatinine rise in 67 patients with bone metastases at one center.
Acquired Fanconi syndrome in an AJKD case series and single-agent reports, resolving on withdrawal.
Tap a signature to trace where it strikes the nephron.
Representative incidence
Acute Tubular Necrosis strikes: Proximal Tubule, Distal Tubule / Collecting Duct.
Acute Tubular Necrosis
Direct death of tubular epithelial cells — the dose-limiting lesion of the platinums and zoledronate.
Nitrogen-containing bisphosphonate inhibiting osteoclast-mediated bone resorption. Hypercalcemia of malignancy, bone metastases and myeloma.
Class-level context for the major non-renal toxicities of the Bisphosphonate class.
Musculoskeletal
Myalgia, myositis, rhabdomyolysis, ONJ
8 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Everything below is FAERS — adverse events someone chose to report, about 66,922 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Counted by the report's active-substance field, which FAERS fills almost only on reports received from 2013 on, so these figures describe reports since then, not the agent's whole history.
Reported with a death outcome
9,004 of 66,922 reports
Reported with hospitalization
19,636 of 66,922 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 4,459 of the 66,922 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Zoledronic acid sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Enhertu · Antibody-drug conjugate (HER2/DXd)
Emerging AKI/proteinuria reports — under-published.
Gleevec · BCR-ABL TKI
Fluid retention; rare Fanconi and AKI.
Zanosar · Nitrosourea alkylator
Classic proximal tubular toxin → Fanconi and dose-limiting AKI.
Vidaza · Hypomethylating agent
Proximal (type 2) RTA / Fanconi-like tubulopathy; overt AKI uncommon.
Revlimid · Immunomodulatory drug (IMiD)
Renally cleared; AKI and rare Fanconi/TMA.
Boniva · Bisphosphonate
Lower renal risk than zoledronate.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to Zoledronic acid’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Zoledronic acid; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 126 clinical records among all 154 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.